Ypsomed Holding AG

Ypsomed Holding AG is a leading Swiss medical technology company specializing in the development and manufacture of injection and infusion systems for self-medication. Renowned as a diabetes care specialist, the company’s core offerings include insulin pumps, autoinjectors, pen injectors, and related medical devices that support the effective treatment of diabetes, infertility, growth disorders, and other chronic conditions. Ypsomed serves both end consumers through its mylife Diabetescare brand, providing products directly to patients, pharmacies, and hospitals, and pharmaceutical and biotechnology companies via Ypsomed Delivery Systems, supplying customized solutions and services for drug delivery. Headquartered in Burgdorf, Switzerland, Ypsomed Holding AG operates a global network of production sites, subsidiaries, and distribution partners, employing over 2,600 people worldwide. As an industry innovator for over four decades, Ypsomed plays a pivotal role in advancing self-administration therapies, supporting the increasing demand for patient-centric solutions in chronic disease management and contributing significantly to the evolving landscape of modern healthcare technology.